Statistik Asas
| CIK | 1858848 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Tenaya Therapeutics, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan senarai kronologi lengkap bagi Pemfailan SEC, tidak termasuk pemfailan pemilikan yang kami sediakan di tempat lain.
| August 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 06, 2025 Tenaya Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40656 81-3789973 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| August 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40656 TENAYA THERAPEUTICS, INC. |
|
| August 6, 2025 |
Exhibit 99.1 Tenaya Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update Enrollment Complete in Cohorts 1 and 2 of MyPEAKTM-1 Phase 1b/2 Trial of TN-201 for MYBPC3-associated HCM; Positive DSMB Safety Review Enables Enrollment of Expansion Cohorts Cohort 1 of RIDGE™-1 Phase 1b Trial of TN-401 Enrolled and First PKP2-associated ARVC Patient Dosed in Cohort 2 Follo |
|
| May 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 28, 2025 Tenaya Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40656 81-3789973 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40656 TENAYA THERAPEUTICS, INC. |
|
| May 7, 2025 |
Exhibit 99.1 Tenaya Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update Interim Data from Low Dose Cohort in MyPEAKTM-1 Clinical Trial of TN-201 Showed Encouraging Safety Profile, Transduction and Expression, Plus Improvements in Hypertrophy and NYHA Classification RIDGE Natural History and Seroprevalence Study Highlights Significant Disease Burden and Unmet Need |
|
| May 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 07, 2025 Tenaya Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40656 81-3789973 (State or Other Jurisdiction of Incorporation) (Commission |
|
| April 18, 2025 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 15, 2025 Tenaya Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40656 81-3789973 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| April 17, 2025 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Pro |
|
| April 17, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defi |
|
| March 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 27, 2025 Tenaya Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40656 81-3789973 (State or other jurisdiction of incorporation) (Commissio |
|
| March 27, 2025 |
CORRESP March 27, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, DC 20549-3720 Attention: Joshua Gorsky Re: Tenaya Therapeutics, Inc. Registration Statement on Form S-3 Filed March 21, 2025 File No. 333-286005 Acceleration Request Requested Date: March 31, 2025 Requested Time: 4:00 P.M. Eastern Time, or |
|
| March 21, 2025 |
Exhibit 107 CALCULATION OF FILING FEE TABLES Form S-3 (Form Type) Tenaya Therapeutics, Inc. |
|
| March 21, 2025 |
Exhibit 4.5 TENAYA THERAPEUTICS, INC. INDENTURE Dated as of , 20 [] Trustee TABLE OF CONTENTS Page ARTICLE I DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1 Definitions 1 Section 1.2 Other Definitions 4 Section 1.3 Incorporation by Reference of Trust Indenture Act 5 Section 1.4 Rules of Construction 5 ARTICLE II THE SECURITIES 5 Section 2.1 Issuable in Series 5 Section 2.2 Establishmen |
|
| March 21, 2025 |
As filed with the Securities and Exchange Commission on March 21, 2025 S-3 Table of Contents As filed with the Securities and Exchange Commission on March 21, 2025 Registration No. |
|
| March 10, 2025 |
Exhibit 4.3 Description of Securities General Tenaya Therapeutics, Inc. (“we,” “our,” or “us”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”): our common stock, $0.0001 par value per share. The following descriptions of our capital stock and certain provisions of our amended and restated certificate of incorporation a |
|
| March 10, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2025 Tenaya Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40656 81-3789973 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| March 10, 2025 |
Exhibit 99.1 Tenaya Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update Dosing Initiated in Cohort 2 of the MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 for Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy MyPEAK-1 Cohort 1 Data Accepted for Late-Breaker Presentation at the American College of Cardiology Meeting Initial Data from RIDGE™- |
|
| March 10, 2025 |
EXHIBIT 19.1 TENAYA THERAPEUTICS, INC. INSIDER TRADING POLICY A. POLICY OVERVIEW Tenaya Therapeutics, Inc. (the “Company”) has adopted this Insider Trading Policy (the “Policy”) to help Covered Persons (as defined below) comply with the federal and state securities laws and regulations that govern trading in securities and to help the Company minimize its own legal and reputational risk. It is eac |
|
| March 10, 2025 |
Employment Letter between the Registrant and Tomohiro Higa, M.B.A. EXHIBIT 10.10 171 Oyster Point Boulevard, Suite 500 South San Francisco, CA 94080 November 26, 2019 Tomohiro Higa Dear Hiro: I am pleased to offer you a position with Tenaya Therapeutics, Inc. (the "Company"), as its Vice President, Finance reporting to Faraz Ali, M.B.A., Chief Executive Officer. If you accept our offer, your first day of employment will be as soon as practicable, but no later tha |
|
| March 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROMTO Commission File Number 001-40656 TENAYA THERAPEUT |
|
| March 4, 2025 |
Form of Series B Warrant to Purchase Common Stock Exhibit 4.2 TENAYA THERAPEUTICS, INC. FORM OF SERIES B WARRANT TO PURCHASE COMMON STOCK Number of Shares: [ ] (subject to adjustment) Warrant No. B-[ ] Original Issue Date: March [ ], 2025 Tenaya Therapeutics, Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [ ] or its registered |
|
| March 4, 2025 |
Table of Contents Filed pursuant to Rule 424(b)(5) Registration No. 333-266741 PROSPECTUS SUPPLEMENT (To prospectus dated August 17, 2022) 75,000,000 UNITS CONSISTING OF ONE SHARE OF COMMON STOCK, ONE SERIES A WARRANT TO PURCHASE COMMON STOCK AND ONE SERIES B WARRANT TO PURCHASE COMMON STOCK SHARES OF COMMON STOCK ISSUABLE UPON THE EXERCISE OF THE SERIES A WARRANTS AND SERIES B WARRANTS We are off |
|
| March 4, 2025 |
Exhibit 1.1 TENAYA THERAPEUTICS, INC. 75,000,000 UNITS CONSISTING OF ONE SHARE OF COMMON STOCK, ONE SERIES A WARRANT TO PURCHASE ONE SHARE OF COMMON STOCK AND ONE SERIES B WARRANT TO PURCHASE ONE-HALF OF A SHARE OF COMMON STOCK UNDERWRITING AGREEMENT March 3, 2025 March 3, 2025 Leerink Partners LLC Piper Sandler & Co. As Representatives of the several Underwriters named in Schedule I hereto c/o Le |
|
| March 4, 2025 |
Form of Series A Warrant to Purchase Common Stock Exhibit 4.1 TENAYA THERAPEUTICS, INC. FORM OF SERIES A WARRANT TO PURCHASE COMMON STOCK Number of Shares: [ ] (subject to adjustment) Warrant No. A-[ ] Original Issue Date: March [ ], 2025 Tenaya Therapeutics, Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [ ] or its registered |
|
| March 4, 2025 |
Tenaya Therapeutics Announces Pricing of Public Offering Exhibit 99.1 Tenaya Therapeutics Announces Pricing of Public Offering South San Francisco, Calif. – March 3, 2025 – Tenaya Therapeutics, Inc. (Nasdaq: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced the pricing of its underwritten public offering of 75,0 |
|
| March 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 3, 2025 Tenaya Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40656 81-3789973 (State or other jurisdiction of incorporation) (Commission |
|
| March 3, 2025 |
SUBJECT TO COMPLETION, DATED MARCH 3, 2025 424B5 Table of Contents Filed pursuant to Rule 424(b)(5) Registration No. 333-266741 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and is effective. This preliminary prospectus supplement and the accompanying prospectus are not an offer to |
|
| March 3, 2025 |
424B3 Filed pursuant to Rule 424(b)(3) Registration No. 333-266741 SUPPLEMENT NO 1. DATED March 3, 2025 TO PROSPECTUS SUPPLEMENT DATED August 17, 2022 (To Prospectus Dated August 17, 2022) Tenaya Therapeutics, Inc. This Supplement No. 1 to Prospectus Supplement (this “Supplement”) supplements and amends the Prospectus Supplement dated August 17, 2022 (the “Prospectus Supplement”). This Supplement |
|
| February 14, 2025 |
EX-99.1 2 ex-99-02142025110237.htm JOINT FILING AGREEMENT EXHIBIT 99.1 JOINT FILING AGREEMENT This Joint Filing Agreement, dated as of February 14, 2025, is by and among RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. (the foregoing are collectively referred to herein as the “Filers”). Each of the Filers may be required to file with the United State |
|
| February 7, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Tenaya Therapeutics, Inc. |
|
| February 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 06, 2025 Tenaya Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40656 81-3789973 (State or Other Jurisdiction of Incorporation) (Commis |
|
| February 7, 2025 |
As filed with the Securities and Exchange Commission on February 7, 2025 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| January 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 24, 2025 Tenaya Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40656 81-3789973 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| December 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 16, 2024 Tenaya Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40656 81-3789973 (State or other jurisdiction of incorporation) (Commis |
|
| December 17, 2024 |
Exhibit 99.1 Tenaya Therapeutics Reports Promising Early Data from MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 for Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy TN-201 Well Tolerated at 3E13 vg/kg Dose AAV9 Capsid Demonstrated Robust Delivery of TN-201 Transgene to Heart Muscle Cells Resulting in Increasing RNA Expression and an Increase in Protein Levels Observed at One Year Circul |
|
| December 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 17, 2024 Tenaya Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40656 81-3789973 (State or other jurisdiction of incorporation) (Commis |
|
| December 17, 2024 |
Phase 1b Study Initial Cohort 1 Data December 17, 2024 Exhibit 99.2 TN-201 MyPEAK-1 Phase 1b Study Initial Cohort 1 Data December 17, 2024 Today’s speakers Milind Desai, M.D., Director at the Cleveland Clinical Faraz Ali, MBA HCM Center; Vice Chair of Heart Chief Executive Officer Vascular Thoracic Institute and MyPEAK-1 investigator Michelle Corral Whit Tingley, M.D., PhD Vice President, Corporate Chief Medical Officer Communications and Investor Re |
|
| November 14, 2024 |
TNYA / Tenaya Therapeutics, Inc. / RA CAPITAL MANAGEMENT, L.P. - SC 13G/A Passive Investment SC 13G/A 1 tm2427451d24sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* Tenaya Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 87990A106 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Stat |
|
| November 14, 2024 |
Exhibit 1: Joint Filing Agreement EX-99.1 2 tm2427451d24ex1.htm EXHIBIT 1 EXHIBIT 1 AGREEMENT This Joint Filing Agreement, dated as of November 14, 2024, is by and among RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. (the foregoing are collectively referred to herein as the “Filers”). Each of the Filers may be required to file with the United States Securities and Exchange Commissi |
|
| November 6, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 06, 2024 Tenaya Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40656 81-3789973 (State or Other Jurisdiction of Incorporation) (Commis |
|
| November 6, 2024 |
Exhibit 99.1 Tenaya Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update Data Safety and Monitoring Board Endorsed Dose Escalation and Broadening of Inclusion Criteria in the MyPEAKTM-1 Phase 1b/2 Trial of TN-201 Gene Therapy Initial TN-201 Data from Cohort 1 of MyPEAK-1 to be Reported in December 2024 SOUTH SAN FRANCISCO, Calif., November 6, 2024 – Tenaya Therape |
|
| November 6, 2024 |
Exhibit 4.1 THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN SECTIONS 6.3 AND 6.4 BELOW, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR, IN THE OPINION OF LEGAL COUNSEL IN FORM AND SUBSTAN |
|
| November 6, 2024 |
Exhibit 10.1 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. [***] INDICATES THAT INFORMATION HAS BEEN REDACTED. LOAN AND SECURITY AGREEMENT This LOAN AND SECURITY AGREEMENT (this “Agreement”) is dated as of the Effective Date between SILICON VALLEY BANK, A DIVISION OF FIR |
|
| November 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40656 TENAYA THERAPEUTICS, INC. |
|
| September 17, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Tenaya Therapeutics, Inc. |
|
| September 17, 2024 |
As filed with the Securities and Exchange Commission on September 16, 2024 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| September 16, 2024 |
Exhibit 10.1 TENAYA THERAPEUTICS, INC. 2024 INDUCEMENT EQUITY INCENTIVE PLAN 1. Purposes of the Plan. The purpose of this Plan is to attract and retain the best available personnel for positions of substantial responsibility by providing an inducement material to individuals entering into employment with the Company or any Parent or Subsidiary of the Company. The Plan permits the grant of Nonstatu |
|
| September 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 12, 2024 Tenaya Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40656 81-3789973 (State or Other Jurisdiction of Incorporation) (Commi |
|
| August 8, 2024 |
Exhibit 99.1 Tenaya Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update Received Rare Pediatric Disease Designation from U.S. Food and Drug Administration for TN-201 for MYBPC3-associated Hypertrophic Cardiomyopathy Received UK Clearance to Initiate Clinical Testing of TN-401 for PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy Established $45 Mil |
|
| August 8, 2024 |
Exhibit 10.1 FIRST AMENDMENT TO LEASE This FIRST AMENDMENT TO LEASE ("First Amendment") is made and entered into as of June 14, 2024, by and between HCP OYSTER POINT III LLC, a Delaware limited liability company ("Landlord"), and TENAYA THERAPEUTICS, INC., a Delaware corporation ("Tenant"). r e c i t a l s : A. Landlord and Tenant (as successor-in-interest to The Column Group, LLC) are parties to |
|
| August 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 08, 2024 Tenaya Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40656 81-3789973 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| August 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40656 TENAYA THERAPEUTICS, INC. |
|
| July 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 19, 2024 Tenaya Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40656 81-3789973 (State or other jurisdiction of incorporation) (Commission |
|
| June 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 25, 2024 Tenaya Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40656 81-3789973 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 31, 2024 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 30, 2024 Tenaya Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40656 81-3789973 (State or other jurisdiction of incorporation) (Commission |
|
| May 14, 2024 |
Exhibit 99.1 Tenaya Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update Initial Data from Ongoing MyPEAKTM-1 Phase 1b of TN-201 Expected in Second Half of 2024 Clinical Sites Activated for RIDGETM-1 Phase 1b Clinical Trial of TN-401 Announced Cost Containment Measures in Alignment with Focus on Generating Data from Clinical-Stage Gene Therapy Programs Raised $47 |
|
| May 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40656 TENAYA THERAPEUTICS, INC. |
|
| May 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2024 Tenaya Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40656 81-3789973 (State or other jurisdiction of incorporation) (Commission |
|
| April 17, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2) |
|
| April 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| March 18, 2024 |
Outside Director Compensation Policy. Exhibit 10.10 TENAYA THERAPEUTICS, INC. OUTSIDE DIRECTOR COMPENSATION POLICY (as most recently amended December 7, 2023) Tenaya Therapeutics, Inc. (the “Company”) believes that the granting of equity and cash compensation to members of the Company’s Board of Directors (the “Board,” and members of the Board, “Directors”) represents an effective tool to attract, retain and reward Directors who are n |
|
| March 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 18, 2024 Tenaya Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40656 81-3789973 (State or other jurisdiction of incorporation) (Commissio |
|
| March 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROMTO Commission File Number 001-40656 TENAYA THERAPE |
|
| March 18, 2024 |
Exhibit 97 Tenaya Therapeutics, Inc. COMPENSATION RECOVERY POLICY As adopted on November 21, 2023 Tenaya Therapeutics, Inc. (the “Company”) is committed to strong corporate governance. As part of this commitment, the Compensation Committee (the “Committee”) of the Company’s Board of Directors (the “Board”) has adopted this clawback policy called the Compensation Recovery Policy (the “Policy”). The |
|
| March 18, 2024 |
Exhibit 99.1 Tenaya Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update Initial Data from Ongoing MyPeak™-1 Phase 1b of TN-201 for MYBPC3-associated HCM Expected in Second Half of 2024 On Track to Dose First Patient in RIDGE™-1Phase 1b Clinical Trial of TN-401 for PKP2-associated ARVC in Second Half 2024 $47 Million Net Proceeds from Recent Financi |
|
| February 14, 2024 |
Exhibit 1: Joint Filing Agreement EXHIBIT 1 AGREEMENT This Joint Filing Agreement, dated as of February 14, 2024, is by and among RA Capital Management, L. |
|
| February 14, 2024 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Tenaya Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 87990A106 (CUSIP Number) December 31, 2023 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pur |
|
| February 14, 2024 |
TNYA / Tenaya Therapeutics, Inc. / COLUMN GROUP III, LP - SC 13D/A Activist Investment SC 13D/A 1 d726884dsc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* TENAYA THERAPEUTICS, INC. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 87990A106 (CUSIP Number) James Evangelista The Column Group 1 Letterman Drive, Building D, Suite DM-900 San F |
|
| February 14, 2024 |
TNYA / Tenaya Therapeutics, Inc. / RA CAPITAL MANAGEMENT, L.P. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Tenaya Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 87990A106 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designat |
|
| February 8, 2024 |
EX-4.1 Exhibit 4.1 TENAYA THERAPEUTICS, INC. FORM OF PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK Number of Shares: [ ] (subject to adjustment) Warrant No. Original Issue Date: [ ], 2024 Tenaya Therapeutics, Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [ ] or its registered ass |
|
| February 8, 2024 |
Tenaya Therapeutics Announces Pricing of Underwritten Offering Exhibit 99.1 Tenaya Therapeutics Announces Pricing of Underwritten Offering South San Francisco, Calif. – February 8, 2024 – Tenaya Therapeutics, Inc. (Nasdaq: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced the pricing of its underwritten offering of 8, |
|
| February 8, 2024 |
Exhibit 1.1 TENAYA THERAPEUTICS, INC. 8,888,890 SHARES OF COMMON STOCK, $0.0001 PAR VALUE PER SHARE PRE-FUNDED WARRANTS TO PURCHASE 2,222,271 SHARES OF COMMON STOCK UNDERWRITING AGREEMENT February 7, 2024 February 7, 2024 Leerink Partners LLC Cowen and Company, LLC As Representatives of the several Underwriters named in Schedule I hereto c/o Leerink Partners LLC 1301 Avenue of the Americas, 12th F |
|
| February 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 7, 2024 Tenaya Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40656 81-3789973 (State or other jurisdiction of incorporation) (Commiss |
|
| February 8, 2024 |
8,888,890 SHARES OF COMMON STOCK PRE-FUNDED WARRANTS TO PURCHASE 2,222,271 SHARES OF COMMON STOCK Table of Contents Filed pursuant to Rule 424(b)(5) Registration No. 333-266741 PROSPECTUS SUPPLEMENT (To prospectus dated August 17, 2022) 8,888,890 SHARES OF COMMON STOCK PRE-FUNDED WARRANTS TO PURCHASE 2,222,271 SHARES OF COMMON STOCK We are offering an aggregate of 8,888,890 shares of our common stock and, in lieu of common stock to certain investors that so choose, pre-funded warrants to purch |
|
| January 31, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Tenaya Therapeutics, Inc. |
|
| January 31, 2024 |
As filed with the Securities and Exchange Commission on January 31, 2024 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| November 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40656 TENAYA THERAPEUTICS, INC. |
|
| November 8, 2023 |
Outside Director Compensation Policy Exhibit 10.1 TENAYA THERAPEUTICS, INC. OUTSIDE DIRECTOR COMPENSATION POLICY (as most recently amended September 14, 2023) Tenaya Therapeutics, Inc. (the “Company”) believes that the granting of equity and cash compensation to members of the Company’s Board of Directors (the “Board,” and members of the Board, “Directors”) represents an effective tool to attract, retain and reward Directors who are |
|
| November 8, 2023 |
Exhibit 99.1 Tenaya Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update Commenced Patient Dosing in MyPeak-1TM Phase 1b Trial of TN-201 in MYBPC3-Associated Hypertrophic Cardiomyopathy Presented Positive Phase 1 Data for TN-301 for the Potential Treatment of Heart Failure with Preserved Ejection Fraction at HFSA 2023 TN-401 for PKP2-Associated ARVC Received FDA C |
|
| November 8, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2023 Tenaya Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40656 81-3789973 (State or other jurisdiction of incorporation) (Commiss |
|
| August 9, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2023 Tenaya Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40656 81-3789973 (State or other jurisdiction of incorporation) (Commissio |
|
| August 9, 2023 |
Composite Amended and Restated Certificate of Incorporation of Tenaya Therapeutics, Inc., as amended Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF TENAYA THERAPEUTICS, INC. a Delaware corporation Tenaya Therapeutics, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Company”), does hereby certify as follows: A. The original Certificate of Incorporation of the Company was filed with the Secretary of State of the State of Delaware on August |
|
| August 9, 2023 |
Exhibit 99.1 Tenaya Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update Dosing of First Patient in Phase 1b Trial of TN-201 On Track to Occur in Q3 2023 Data from Phase 1 Clinical Trial of TN-301 Accepted for Presentation at HFSA 2023 IND Application for TN-401 Anticipated in Second Half 2023 Second Quarter Cash and Investments of $152 Million; Runway to Fund Op |
|
| August 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40656 TENAYA THERAPEUTICS, INC. |
|
| June 12, 2023 |
Executive Change in Control and Severance Plan. Exhibit 10.1 TENAYA THERAPEUTICS, INC. EXECUTIVE CHANGE IN CONTROL AND SEVERANCE PLAN AND SUMMARY PLAN DESCRIPTION 1. Introduction. The purpose of this Tenaya Therapeutics, Inc. Executive Change in Control and Severance Plan (the “Plan”) is to provide assurances of specified benefits to certain employees of the Company whose employment could be being involuntarily terminated other than for death, |
|
| June 12, 2023 |
Exhibit 3.1 Certificate of Amendment to THE Amended and Restated Certificate of Incorporation of TENAYA THERAPEUTICS, Inc. Tenaya Therapeutics, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), hereby certifies as follows: 1. The name of the Corporation is Tenaya Therapeutics, Inc. The original Certificate of Incorporation of the Corporation wa |
|
| June 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 8, 2023 Tenaya Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40656 81-3789973 (State or other jurisdiction of incorporation) (Commission |
|
| May 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2023 Tenaya Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40656 81-3789973 (State or other jurisdiction of incorporation) (Commission |
|
| May 10, 2023 |
Exhibit 99.1 Tenaya Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update TN-201 Received Fast Track Designation from the FDA Dosing Complete in Phase 1 Clinical Trial of TN-301; Data Expected in Second Half 2023 Renowned Researchers Drs. Christine Seidman and Alex Marson Join Scientific Advisory Board Announces Formation of Technical Advisory Board with Deep Exper |
|
| May 10, 2023 |
Outside Director Compensation Policy Exhibit 10.1 TENAYA THERAPEUTICS, INC. OUTSIDE DIRECTOR COMPENSATION POLICY (as most recently amended and restated March 16, 2023 (the “Restatement Date”)) Tenaya Therapeutics, Inc. (the “Company”) believes that the granting of equity and cash compensation to members of the Company’s Board of Directors (the “Board,” and members of the Board, “Directors”) represents an effective tool to attract, re |
|
| May 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40656 TENAYA THERAPEUTICS, INC. |
|
| April 27, 2023 |
DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 27, 2023 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Pro |
|
| April 17, 2023 |
PRE 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 21, 2023 |
Amended and Restated Bylaws of Tenaya Therapeutics, Inc. Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF TENAYA THERAPEUTICS, INC. (initially adopted on August 18, 2016) (as amended and restated on August 3, 2021 and March 16, 2023) TABLE OF CONTENTS Page ARTICLE I - CORPORATE OFFICES 1 1.1 REGISTERED OFFICE 1 1.2 OTHER OFFICES 1 ARTICLE II - MEETINGS OF STOCKHOLDERS 1 2.1 PLACE OF MEETINGS 1 2.2 ANNUAL MEETING 1 2.3 SPECIAL MEETING 1 2.4 ADVANCE NOTICE PROC |
|
| March 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 16, 2023 Tenaya Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40656 81-3789973 (State or other jurisdiction of incorporation) (Commissio |
|
| March 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2023 Tenaya Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40656 81-3789973 (State or other jurisdiction of incorporation) (Commissio |
|
| March 8, 2023 |
As filed with the Securities and Exchange Commission on March 8, 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 8, 2023 |
Exhibit 99.1 Tenaya Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update TN-201 IND Cleared in January; Plan to Begin Phase 1b Dosing in MYBPC3-associated HCM Patients in Third Quarter 2023 Dosing Commenced in Multiple-Ascending Dose Stage of First-In-Human Clinical Trial of TN-301; Data Anticipated in Second Half 2023 2022 Year End Cash and Investm |
|
| March 8, 2023 |
Outside Director Compensation Policy. Exhibit 10.10 TENAYA THERAPEUTICS, INC. OUTSIDE DIRECTOR COMPENSATION POLICY (as most recently amended and restated December 5, 2022 (the “Restatement Date”)) Tenaya Therapeutics, Inc. (the “Company”) believes that the granting of equity and cash compensation to members of the Company’s Board of Directors (the “Board,” and members of the Board, “Directors”) represents an effective tool to attract, |
|
| March 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROMTO Commission File Number 001-40656 TENAYA THERAPEUT |
|
| March 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 8, 2023 Tenaya Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40656 81-3789973 (State or other jurisdiction of incorporation) (Commission |
|
| March 8, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Tenaya Therapeutics, Inc. |
|
| February 21, 2023 |
TNYA / Tenaya Therapeutics Inc / COLUMN GROUP III, LP - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* TENAYA THERAPEUTICS, INC. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 87990A106 (CUSIP Number) James Evangelista The Column Group 1 Letterman Drive, Building D, Suite DM-900 San Francisco, CA 94129 (415) 865-2 |
|
| February 14, 2023 |
TNYA / Tenaya Therapeutics, Inc. / RA CAPITAL MANAGEMENT, L.P. - SC 13G/A Passive Investment SC 13G/A 1 tm236221d32sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Tenaya Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 87990A106 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statem |
|
| December 7, 2022 |
Tenaya Therapeutics Appoints Amy Burroughs to Board of Directors Exhibit 99.1 Tenaya Therapeutics Appoints Amy Burroughs to Board of Directors SOUTH SAN FRANCISCO, Calif., ? December 7, 2022 ? Tenaya Therapeutics, Inc. (Nasdaq: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced the appointment of Amy Burroughs to its Boa |
|
| December 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 5, 2022 Tenaya Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40656 81-3789973 (State or other jurisdiction of incorporation) (Commiss |
|
| December 7, 2022 |
TNYA / Tenaya Therapeutics, Inc. / Casdin Capital, LLC Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. |
|
| December 1, 2022 |
Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that the foregoing statement on Schedule 13D is filed on behalf of each of the undersigned, and any amendments thereto executed by the undersigned shall be filed on behalf of each of the undersigned without the necessity of filing any additional joint filing agreement. |
|
| December 1, 2022 |
TNYA / Tenaya Therapeutics, Inc. / COLUMN GROUP III, LP - SC 13D Activist Investment SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No.)* TENAYA THERAPEUTICS, INC. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 87990A106 (CUSIP Number) James Evangelista The Column Group 1 Letterman Drive, Building D, Suite DM-900 San Francisco, CA 94129 (415) 865-2050 |
|
| November 28, 2022 |
TNYA / Tenaya Therapeutics, Inc. / Casdin Capital, LLC Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. |
|
| November 17, 2022 |
Tenaya Therapeutics Announces Pricing of Public Offering Exhibit 99.1 Tenaya Therapeutics Announces Pricing of Public Offering South San Francisco, Calif. ? November 17, 2022 ? Tenaya Therapeutics, Inc. (Nasdaq: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced the pricing of its underwritten public offering of |
|
| November 17, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 16, 2022 Tenaya Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40656 81-3789973 (State or other jurisdiction of incorporation) (Commis |
|
| November 17, 2022 |
EX-1.1 2 d383621dex11.htm EX-1.1 Exhibit 1.1 UNDERWRITING AGREEMENT 22,613,307 SHARES OF COMMON STOCK, $0.0001 PAR VALUE PER SHARE PRE-FUNDED WARRANTS TO PURCHASE 6,236,693 SHARES OF COMMON STOCK TENAYA THERAPEUTICS, INC. November 16, 2022 November 16, 2022 Morgan Stanley & Co. LLC Piper Sandler & Co. As Representatives of the several Underwriters named in Schedule I hereto c/o Morgan Stanley & Co |
|
| November 17, 2022 |
22,613,307 SHARES OF COMMON STOCK PRE-FUNDED WARRANTS TO PURCHASE 6,236,693 SHARES OF COMMON STOCK 424B5 1 d417969d424b5.htm 424B5 Table of Contents Filed pursuant to Rule 424(b)(5) Registration No. 333-266741 PROSPECTUS SUPPLEMENT (To prospectus dated August 17, 2022) 22,613,307 SHARES OF COMMON STOCK PRE-FUNDED WARRANTS TO PURCHASE 6,236,693 SHARES OF COMMON STOCK We are offering 22,613,307 shares of our common stock and, in lieu of common stock to certain investors that so choose, pre-funded |
|
| November 17, 2022 |
Exhibit 4.1 TENAYA THERAPEUTICS, INC. FORM OF PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK Number of Shares: [ ] (subject to adjustment) Warrant No. Original Issue Date: [ ], 2022 Tenaya Therapeutics, Inc., a Delaware corporation (the ?Company?), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [ ] or its registered assigns (t |
|
| November 16, 2022 |
$75,000,000 COMMON STOCK PRE-FUNDED WARRANTS TO PURCHASE SHARES OF COMMON STOCK 424B5 Table of Contents Filed pursuant to Rule 424(b)(5) Registration No. 333-266741 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and is effective. This preliminary prospectus supplement and the accompanying prospectus are not an offer to |
|
| November 10, 2022 |
Exhibit 99.1 Tenaya Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update Extends Cash Runway to Mid-2024 Commenced Dosing in Phase 1 Clinical Trial of TN-301; Data Expected in 2023 Plans to Submit TN-201 IND by Year End South San Francisco, Calif. ? November 10, 2022?Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to |
|
| November 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40656 TENAYA THERAPEUTICS, INC. |
|
| November 10, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2022 Tenaya Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40656 81-3789973 (State or other jurisdiction of incorporation) (Commis |
|
| August 17, 2022 |
Up to $75,000,000 COMMON STOCK Table of Contents Filed pursuant to Rule 424(b)(5) Registration No. 333-266741 PROSPECTUS SUPPLEMENT (To prospectus dated August 17, 2022) Up to $75,000,000 COMMON STOCK We have entered into a sales agreement with SVB Securities LLC (SVB Securities), relating to shares of our common stock, par value $0.0001 per share, offered by this prospectus supplement and the accompanying prospectus. In accord |
|
| August 15, 2022 |
August 15, 2022 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, DC 20549-3720 Attention: Joshua Gorsky Re: Tenaya Therapeutics, Inc. Registration Statement on Form S-3 Filed August 10, 2022 File No. 333-266741 Acceleration Request Requested Date: August 17, 2022 Requested Time: 4:00 P.M. Eastern Time, or as so |
|
| August 10, 2022 |
Exhibit 1.1 TENAYA THERAPEUTICS, INC. Shares of Common Stock ($0.0001 par value per share) SALES AGREEMENT August 10, 2022 SVB SECURITIES LLC 1301 Avenue of the Americas, 12th Floor New York, New York 10019 Ladies and Gentlemen: Tenaya Therapeutics, Inc., a Delaware corporation (the ?Company?), confirms its agreement (this ?Agreement?) with SVB Securities LLC (the ?Agent?), as follows: 1. Issuance |
|
| August 10, 2022 |
Exhibit 107 Calculation of Filing Fee Tables FORM S-3 (Form Type) TENAYA THERAPEUTICS, INC. |
|
| August 10, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2022 Tenaya Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40656 81-3789973 (State or other jurisdiction of incorporation) (Commissi |
|
| August 10, 2022 |
As filed with the Securities and Exchange Commission on August 10, 2022 Table of Contents As filed with the Securities and Exchange Commission on August 10, 2022 Registration No. |
|
| August 10, 2022 |
Exhibit 4.5 TENAYA THERAPEUTICS, INC. INDENTURE Dated as of , 20 [ ] Trustee TABLE OF CONTENTS Page ARTICLE I DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1 Definitions 1 Section 1.2 Other Definitions 4 Section 1.3 Incorporation by Reference of Trust Indenture Act 5 Section 1.4 Rules of Construction 5 ARTICLE II THE SECURITIES 5 Section 2.1 Issuable in Series 5 Section 2.2 Establishment |
|
| August 10, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2022 Tenaya Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40656 81-3789973 (State or other jurisdiction of incorporation) (Commissi |
|
| August 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40656 TENAYA THERAPEUTICS, INC. |
|
| August 10, 2022 |
Exhibit 1.2 TENAYA THERAPEUTICS, INC. Shares of Common Stock ($0.0001 par value per share) SALES AGREEMENT August 10, 2022 SVB SECURITIES LLC 1301 Avenue of the Americas, 12th Floor New York, New York 10019 Ladies and Gentlemen: Tenaya Therapeutics, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with SVB Securities LLC (the “Agent”), as follows: 1. Issuance |
|
| August 10, 2022 |
Exhibit 99.1 + Tenaya Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update Received State Licensing to Enable cGMP Manufacturing of Drug Product TN-201 and TN-301 IND Submissions on Track for Second Half 2022 Presented Preclinical Data for Multiple Pipeline Programs and Capsid Engineering Efforts South San Francisco, Calif. – Aug. 10, 2022—Tenaya Therapeutics, In |
|
| June 10, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2022 Tenaya Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40656 81-3789973 (State or other jurisdiction of incorporation) (Commission |
|
| May 11, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2022 Tenaya Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40656 81-3789973 (State or other jurisdiction of incorporation) (Commission |
|
| May 11, 2022 |
Exhibit 99.1 Tenaya Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update TN-201 Received Orphan Medicinal Product Designation from the European Commission Preclinical TN-401 Data Presented at Heart Rhythm 2022 South San Francisco, Calif. ? May 11, 2022?Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a biotechnology company with a mission to discover, develop and deliver |
|
| May 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40656 TENAYA THERAPEUTICS, INC. |
|
| April 28, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defi |
|
| April 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| March 23, 2022 |
2021 Equity Incentive Plan and forms of agreements thereunder. Exhibit 10.2 TENAYA THERAPEUTICS, INC. 2021 EQUITY INCENTIVE PLAN 1. Purposes of the Plan. The purposes of this Plan are: ? to attract and retain the best available personnel for positions of substantial responsibility, ? to provide additional incentive to Employees, Directors and Consultants, and ? to promote the success of the Company?s business. The Plan permits the grant of Incentive Stock Opt |
|
| March 23, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Tenaya Therapeutics, Inc. |
|
| March 23, 2022 |
Exhibit 4.3 Description of Securities General Tenaya Therapeutics, Inc. (?we,? ?our,? or ?us?) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the ?Exchange Act?): our common stock $0.0001 par value per share. The following descriptions of our capital stock and certain provisions of our amended and restated certificate of incorporation an |
|
| March 23, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 23, 2022 Tenaya Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40656 81-3789973 (State or other jurisdiction of incorporation) (Commissio |
|
| March 23, 2022 |
As filed with the Securities and Exchange Commission on March 23, 2022 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 23, 2022 |
Exhibit 99.1 Tenaya Therapeutics Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Business Updates Strengthened Leadership Team with the Additions of Sunita Sethi as Senior Vice President of Regulatory Affairs and Naymisha Patel as Senior Vice President of Quality South San Francisco, Calif. ? March 23, 2022?Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a biotechnology company w |
|
| March 23, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROMTO Commission File Number 001-40656 TENAYA THERAPEUT |
|
| February 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 Under the Securities Exchange Act of 1934 (AMENDMENT NO. 1) Tenaya Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securi |
|
| February 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 Under the Securities Exchange Act of 1934 (AMENDMENT NO. 1) Clene Inc. (Name of Issuer) Common Stock, $.0001 par value (Title of Class of Securities) G8959N130 |
|
| February 14, 2022 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Tenaya Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 87990A106 (CUSIP Number) December 31, 2021 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursua |
|
| February 14, 2022 |
TNYA / Tenaya Therapeutics, Inc. / Ugwumba Chidozie - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 (AMENDMENT NO. ) Tenaya Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 87990A106 (CUSIP Number) December 31, |
|
| February 11, 2022 |
JOINT FILING AGREEMENT The undersigned hereby agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned, and any amendments thereto executed by the undersigned shall be filed on behalf of each of the undersigned without the necessity of filing any additional joint filing agreement. |
|
| February 11, 2022 |
TNYA / Tenaya Therapeutics, Inc. / COLUMN GROUP III, LP - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* TENAYA THERAPEUTICS, INC. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 87990A106 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate t |
|
| December 22, 2021 |
Exhibit 99.1 Tenaya Therapeutics appoints Karah Parschauer, J.D., to its Board of Directors and Joanna Auch as Senior Vice President of People and Culture SOUTH SAN FRANCISCO, Calif., ? December 22, 2021 ? Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a biotechnology company with a mission to discover, develop and deliver curative therapies that address the underlying causes of heart disease, today an |
|
| December 22, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 22, 2021 Tenaya Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40656 81-3789973 (State or other jurisdiction of incorporation) (Commis |
|
| November 22, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 17, 2021 Tenaya Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40656 81-3789973 (State or other jurisdiction of incorporation) (Commis |
|
| November 22, 2021 |
Tenaya Therapeutics Announces the Addition of Dr. June Lee to its Board of Directors Exhibit 99.1 Tenaya Therapeutics Announces the Addition of Dr. June Lee to its Board of Directors SOUTH SAN FRANCISCO, Calif.?(BUSINESS WIRE)?Nov. 22, 2021? Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a biotechnology company with a mission to discover, develop and deliver curative therapies that address the underlying causes of heart disease, today announced changes to its Board of Directors includin |
|
| November 10, 2021 |
Tenaya Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Updates Exhibit 99.1 Tenaya Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Updates - Initiated global natural history study for pediatric patients with MYBPC3 mutation to support clinical development of TN-201 gene therapy - Presented preclinical data supporting both TN-201 and PKP2 gene therapy programs at the European Society of Gene and Cell Therapy conference demonstra |
|
| November 10, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2021 Tenaya Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40656 81-3789973 (State or other jurisdiction of incorporation) (Commis |
|
| November 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40656 TENAYA THERAPEUTICS, INC. |
|
| September 8, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 8, 2021 Tenaya Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40656 81-3789973 (State or other jurisdiction of incorporation) (Commis |
|
| September 8, 2021 |
Exhibit 99.1 Tenaya Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Updates ? TN-201 MYBPC3 gene therapy product candidate for the leading genetic cause of hypertrophic cardiomyopathy granted Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA) ? Expanded leadership team appointing Leone Patterson as Chief Financial and Business Officer and |
|
| September 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40656 TENAYA THERAPEUTICS, INC. |
|
| August 9, 2021 |
TNYA / Tenaya Therapeutics, Inc. / Casdin Capital, LLC Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. |
|
| August 9, 2021 |
TNYA / Tenaya Therapeutics, Inc. / RA CAPITAL MANAGEMENT, L.P. - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Tenaya Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 87990A106 (CUSIP Number) July 30, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the r |
|
| August 9, 2021 |
TNYA / Tenaya Therapeutics, Inc. / Walton Thomas Layton - SCHEDULE 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 (AMENDMENT NO. ) Tenaya Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 87990A106 (CUSIP Number) August 3, 2021 (Date of Ev |
|
| August 3, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2021 Tenaya Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40656 81-3789973 (State or other jurisdiction of incorporation) (Commissio |
|
| August 3, 2021 |
Amended and Restated Bylaws of Tenaya Therapeutics, Inc. Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF TENAYA THERAPEUTICS, INC. (initially adopted on August 18, 2016) (as amended and restated on August 3, 2021) TABLE OF CONTENTS Page ARTICLE I - CORPORATE OFFICES 1 1.1 REGISTERED OFFICE 1 1.2 OTHER OFFICES 1 ARTICLE II - MEETINGS OF STOCKHOLDERS 1 2.1 PLACE OF MEETINGS 1 2.2 ANNUAL MEETING 1 2.3 SPECIAL MEETING 1 2.4 ADVANCE NOTICE PROCEDURES 2 2.5 NOTICE |
|
| August 3, 2021 |
Exhibit 99.1 Tenaya Therapeutics Announces Closing of Upsized Initial Public Offering and Exercise in Full of the Underwriters? Option to Purchase Additional Shares SOUTH SAN FRANCISCO, Calif., August 3, 2021 ? Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a biotechnology company with a mission to discover, develop and deliver curative therapies that address the underlying causes of heart disease, ann |
|
| August 3, 2021 |
Amended and Restated Certificate of Incorporation of Tenaya Therapeutics, Inc. Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF TENAYA THERAPEUTICS, INC. a Delaware corporation Tenaya Therapeutics, Inc., a corporation organized and existing under the laws of the State of Delaware (the ?Company?), does hereby certify as follows: A. The original Certificate of Incorporation of the Company was filed with the Secretary of State of the State of Delaware on August |
|
| July 30, 2021 |
12,000,000 Shares Common Stock Table of Contents Filed pursuant to 424(b)(4) Registration Nos. 333-257820 and 333-258285 PROSPECTUS 12,000,000 Shares Common Stock Tenaya Therapeutics, Inc. is offering 12,000,000 shares of our common stock. This is the initial public offering, and no public market currently exists for our shares of common stock. The initial public offering price is $15.00 per share. Our common stock has been app |
|
| July 30, 2021 |
As filed with the Securities and Exchange Commission on July 30, 2021 As filed with the Securities and Exchange Commission on July 30, 2021 Registration No. |
|
| July 29, 2021 |
As filed with the Securities and Exchange Commission on July 29, 2021. As filed with the Securities and Exchange Commission on July 29, 2021. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT Under The Securities Act of 1933 TENAYA THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware 2836 82-3789973 (State or other jurisdiction of incorporation or organization) ( |
|
| July 27, 2021 |
[Signature page immediately follows] CORRESP 1 filename1.htm Morgan Stanley & Co. LLC 1585 Broadway New York, New York 10036 Cowen and Company, LLC 599 Lexington Avenue New York, New York 10022 Piper Sandler & Co. 800 Nicollet Mall, Suite 800 Minneapolis, MN 55402 July 27, 2021 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attn: Tracey Ho |
|
| July 27, 2021 |
CORRESP 1 filename1.htm July 27, 2021 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attention: Tracey Houser Brian Cascio Tom Kluck Suzanne Hayes Re: Tenaya Therapeutics, Inc. Registration Statement on Form S-1 (File No. 333-257820) Acceleration Request Requested Date: Thursday, July 29, 2021 Requ |
|
| July 26, 2021 |
Form of Underwriting Agreement. Exhibit 1.1 UNDERWRITING AGREEMENT [•] Shares TENAYA THERAPEUTICS, INC. COMMON STOCK, $0.0001 PAR VALUE PER SHARE [•], 2021 [•], 2021 Morgan Stanley & Co. LLC Cowen and Company, LLC Piper Sandler & Co. As Representatives of the several Underwriters named in Schedule I hereto c/o Morgan Stanley & Co. LLC 1585 Broadway New York, New York 10036 c/o Cowen and Company, LLC 599 Lexington Avenue New York |
|
| July 26, 2021 |
Specimen common stock certificate of the Registrant. Exhibit 4.2 Exhibit 4.2 ZQ|CERT#|COY|CLS|RGSTRY|ACCT#|TRANSTYPE|RUN#|TRANS# COMMON STOCK COMMON STOCK PAR VALUE $0.0001 Certificate Shares Number * * 000000 ****************** * * * 000000 ***************** ZQ00000000 **** 000000 **************** TENAYA THERAPEUTICS, INC. ***** 000000 *************** ****** 000000 ************** INCORPORATED UNDER THE LAWS OF THE STATE OF DELAWARE THIS CERTIFIES T |
|
| July 26, 2021 |
Outside Director Compensation Policy. Exhibit 10.14 TENAYA THERAPEUTICS, INC. OUTSIDE DIRECTOR COMPENSATION POLICY Tenaya Therapeutics, Inc. (the “Company”) believes that the granting of equity and cash compensation to members of the Company’s Board of Directors (the “Board,” and members of the Board, “Directors”) represents an effective tool to attract, retain and reward Directors who are not employees of the Company (“Outside Direct |
|
| July 26, 2021 |
As filed with the Securities and Exchange Commission on July 26, 2021. S-1/A 1 d175698ds1a.htm S-1/A Table of Contents As filed with the Securities and Exchange Commission on July 26, 2021. Registration No. 333-257820 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT Under the Securities Act of 1933 TENAYA THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware (State |
|
| July 26, 2021 |
Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF TENAYA THERAPEUTICS, INC. Tenaya Therapeutics, Inc., a corporation organized and existing under the laws of the State of Delaware (the ?Corporation?), certifies that: 1. The name of the Corporation is Tenaya Therapeutics, Inc. The Corporation?s original Certificate of Incorporation was filed with the Secretary of State of the State o |
|
| July 26, 2021 |
CORRESP 1 filename1.htm 650 Page Mill Road Palo Alto, CA 94304-1050 650.493.9300 650.493.6811 www.wsgr.com July 26, 2021 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attention: Tracey Houser Brian Cascio Tom Kluck Suzanne Hayes Re: Tenaya Therapeutics, Inc. Registration Statement on Form S-1 File |
|
| July 26, 2021 |
2021 Equity Incentive Plan and forms of agreements thereunder. Exhibit 10.3 TENAYA THERAPEUTICS, INC. 2021 EQUITY INCENTIVE PLAN 1. Purposes of the Plan. The purposes of this Plan are: ? to attract and retain the best available personnel for positions of substantial responsibility, ? to provide additional incentive to Employees, Directors and Consultants, and ? to promote the success of the Company?s business. The Plan permits the grant of Incentive Stock Opt |
|
| July 26, 2021 |
2021 Employee Stock Purchase Plan and forms of agreements thereunder. Exhibit 10.4 TENAYA THERAPEUTICS, INC. 2021 EMPLOYEE STOCK PURCHASE PLAN 1. Purpose. The purpose of the Plan is to provide employees of the Company and its Designated Companies with an opportunity to purchase Common Stock through accumulated Contributions. The Company intends for the Plan to have two components: a component that is intended to qualify as an ?employee stock purchase plan? under Cod |
|
| July 23, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 TENAYA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 81-3789973 (State of incorporation or organization) (I.R.S. Employer Identification No.) 171 Oyster Point B |
|
| July 9, 2021 |
Exhibit 3.2 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF TENAYA THERAPEUTICS, INC. a Delaware corporation Tenaya Therapeutics, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Company”), does hereby certify as follows: A. The original Certificate of Incorporation of the Company was filed with the Secretary of State of the State of Delaware on August |
|
| July 9, 2021 |
Lease between HCP Oyster Point III LLC and the Registrant dated as of September 6, 2016. Exhibit 10.10 THE COVE AT OYSTER POINT LEASE This Lease (the ?Lease?), dated as of the date set forth in Section 1 of the Summary of Basic Lease Information (the ?Summary?), below, is made by and between HCP OYSTER POINT III LLC, a Delaware limited liability company (?Landlord?), and THE COLUMN GROUP, LLC, a Delaware limited liability company (?Tenant?). SUMMARY OF BASIC LEASE INFORMATION TERMS OF |
|
| July 9, 2021 |
Exhibit 3.4 AMENDED AND RESTATED BYLAWS OF TENAYA THERAPEUTICS, INC. (initially adopted on August 18, 2016) (as amended and restated on , 2021) TABLE OF CONTENTS Page ARTICLE I - CORPORATE OFFICES 1 1.1 REGISTERED OFFICE 1 1.2 OTHER OFFICES 1 ARTICLE II - MEETINGS OF STOCKHOLDERS 1 2.1 PLACE OF MEETINGS 1 2.2 ANNUAL MEETING 1 2.3 SPECIAL MEETING 1 2.4 ADVANCE NOTICE PROCEDURES 2 2.5 NOTICE OF STOC |
|
| July 9, 2021 |
Exhibit 4.1 TENAYA THERAPEUTICS, INC. AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT December 17, 2020 TENAYA THERAPEUTICS, INC. AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT This Amended and Restated Investors’ Rights Agreement (this “Agreement”) is dated as of December 17, 2020, and is between Tenaya Therapeutics, Inc., a Delaware corporation (the “Company”), and the persons and entities li |
|
| July 9, 2021 |
As filed with the Securities and Exchange Commission on July 9, 2021. Table of Contents As filed with the Securities and Exchange Commission on July 9, 2021. |
|
| July 9, 2021 |
Bylaws of the Registrant, as currently in effect. Exhibit 3.3 BYLAWS OF TENAYA THERAPEUTICS, INC. Adopted August 18, 2016 TABLE OF CONTENTS Page ARTICLE I — MEETINGS OF STOCKHOLDERS 1 1.1 Place of Meetings 1 1.2 Annual Meeting 1 1.3 Special Meeting 1 1.4 Notice of Stockholders’ Meetings 1 1.5 Quorum 2 1.6 Adjourned Meeting; Notice 2 1.7 Conduct of Business 2 1.8 Voting 2 1.9 Stockholder Action by Written Consent Without a Meeting 3 1.10 Record Da |
|
| July 9, 2021 |
Employment Letter between the Registrant and Faraz Ali, M.B.A. Exhibit 10.5 June 28, 2021 Faraz Ali c/o Tenaya Therapeutics, Inc. Re: Confirmatory Employment Letter Dear Faraz: This confirmatory employment letter agreement (the ?Agreement?) is entered into between you and Tenaya Therapeutics, Inc. (the ?Company? or ?we?), effective as of the effective date of the Company?s registration statement relating to the Company?s initial public offering (the ?Effectiv |
|
| July 9, 2021 |
Amended and Restated 2016 Equity Incentive Plan and forms of agreement thereunder. Exhibit 10.2 TENAYA THERAPEUTICS, INC. AMENDED AND RESTATED 2016 EQUITY INCENTIVE PLAN ORIGINAL PLAN ADOPTED BY THE BOARD OF DIRECTORS: OCTOBER 2, 2016 ORIGINAL PLAN APPROVED BY THE STOCKHOLDERS: OCTOBER 12, 2016 AMENDED AND RESTATED PLAN ADOPTED BY THE BOARD OF DIRECTORS: AUGUST 28, 2019 AMENDED AND RESTATED PLAN ADOPTED BY THE STOCKHOLDERS: AUGUST 28, 2019 AMENDED AND RESTATED PLAN ADOPTED BY TH |
|
| July 9, 2021 |
Executive Change in Control and Severance Plan. Exhibit 10.12 TENAYA THERAPEUTICS, INC. EXECUTIVE CHANGE IN CONTROL AND SEVERANCE PLAN AND SUMMARY PLAN DESCRIPTION 1. Introduction. The purpose of this Tenaya Therapeutics, Inc. Executive Change in Control and Severance Plan (the “Plan”) is to provide assurances of specified benefits to certain employees of the Company whose employment could be being involuntarily terminated other than for death, |
|
| July 9, 2021 |
Lease between Terreno Park Union City LLC and the Registrant dated as of February 12, 2021. Exhibit 10.11 INDUSTRIAL LEASE ? MULTI-TENANT by and between TERRENO PARK UNION CITY LLC ?LANDLORD? and TENAYA THERAPEUTICS, INC. ?TENANT? Dated: February 12, 2021 TERRENO REALTY CORPORATION INDUSTRIAL LEASE 1. Basic Provisions (?Basic Provisions?). 1.1 Parties: This Lease (?Lease?) dated February 12, 2021, is made by and between Terreno Park Union City LLC, a Delaware limited liability company (? |
|
| July 9, 2021 |
Exhibit 10.1 TENAYA THERAPEUTICS, INC. INDEMNIFICATION AGREEMENT This Indemnification Agreement (this “Agreement”) is dated as of [insert date], and is between Tenaya Therapeutics, Inc., a Delaware corporation (the “Company”), and [insert name of indemnitee] (“Indemnitee”). RECITALS A. Indemnitee’s service to the Company substantially benefits the Company. B. Individuals are reluctant to serve as |
|
| July 9, 2021 |
Executive Incentive Compensation Plan. Exhibit 10.13 TENAYA THERAPEUTICS, INC. EXECUTIVE INCENTIVE COMPENSATION PLAN 1. Purposes of the Plan. The Plan is intended to increase stockholder value and the success of the Company by motivating Employees to (a) perform to the best of their abilities and (b) achieve the Company’s objectives. 2. Definitions. 2.1 “Actual Award” means as to any Performance Period, the actual award (if any) payabl |
|
| July 9, 2021 |
Employment Letter between the Registrant and Leone D. Patterson, M.B.A. Exhibit 10.7 Leone Patterson June 18, 2021 Dear Leone: On behalf of Tenaya Therapeutics, Inc. (“we” or the “Company”), I am pleased to invite you to join the Company on the terms and conditions set forth in this letter agreement (the “Agreement”), effective as of the date on which you commence employment with the Company (the “Effective Date”). We look forward to the possibility of your joining ou |
|
| July 9, 2021 |
Amended and Restated Certificate of Incorporation of the Registrant, as currently in effect. Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF TENAYA THERAPEUTICS, INC. Tenaya Therapeutics, Inc., a corporation organized and existing under the laws of the State of Delaware (the ?Corporation?), certifies that: 1. The name of the Corporation is Tenaya Therapeutics, Inc. The Corporation?s original Certificate of Incorporation was filed with the Secretary of State of the State o |
|
| July 9, 2021 |
Employment Letter between the Registrant and Whittemore (Whit) Tingley, M.D., Ph.D. Exhibit 10.8 June 25, 2021 Whittemore Tingley c/o Tenaya Therapeutics, Inc. Re: Confirmatory Employment Letter Dear Whit: This confirmatory employment letter agreement (the “Agreement”) is entered into between you and Tenaya Therapeutics, Inc. (the “Company” or “we”), effective as of the effective date of the Company’s registration statement relating to the Company’s initial public offering (the “ |
|
| July 9, 2021 |
650 Page Mill Road Palo Alto, CA 94304-1050 650.493.9300 650.493.6811 www.wsgr.com July 9, 2021 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attention: Brian Cascio Tracey Houser Tom Kluck Suzanne Hayes Re: Tenaya Therapeutics, Inc. Amended Draft Registration Statement on Form S-1 Submitted June |
|
| July 9, 2021 |
Employment Letter between the Registrant and Timothy Hoey, Ph.D Exhibit 10.6 June 25, 2021 Timothy Hoey c/o Tenaya Therapeutics, Inc. Re: Confirmatory Employment Letter Dear Tim: This confirmatory employment letter agreement (the “Agreement”) is entered into between you and Tenaya Therapeutics, Inc. (the “Company” or “we”), effective as of the effective date of the Company’s registration statement relating to the Company’s initial public offering (the “Effecti |
|
| July 9, 2021 |
Exhibit 10.9 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. [***] INDICATES THAT INFORMATION HAS BEEN REDACTED. LICENSE AGREEMENT This License Agreement (this “Agreement”) is dated as of January 10, 2020 (the “Effective Date”) by and between The Board of Regents (“Board”) |
|
| June 16, 2021 |
EX-10.2 2 filename2.htm Exhibit 10.2 TENAYA THERAPEUTICS, INC. AMENDED AND RESTATED 2016 EQUITY INCENTIVE PLAN ORIGINAL PLAN ADOPTED BY THE BOARD OF DIRECTORS: OCTOBER 2, 2016 ORIGINAL PLAN APPROVED BY THE STOCKHOLDERS: OCTOBER 12, 2016 AMENDED AND RESTATED PLAN ADOPTED BY THE BOARD OF DIRECTORS: AUGUST 28, 2019 AMENDED AND RESTATED PLAN ADOPTED BY THE STOCKHOLDERS: AUGUST 28, 2019 AMENDED AND RES |
|
| June 16, 2021 |
Exhibit 10.10 THE COVE AT OYSTER POINT LEASE This Lease (the ?Lease?), dated as of the date set forth in Section 1 of the Summary of Basic Lease Information (the ?Summary?), below, is made by and between HCP OYSTER POINT III LLC, a Delaware limited liability company (?Landlord?), and THE COLUMN GROUP, LLC, a Delaware limited liability company (?Tenant?). SUMMARY OF BASIC LEASE INFORMATION TERMS OF |
|
| June 16, 2021 |
Table of Contents Amendment No. 1 to Draft Registration Statement, as confidentially submitted to the Securities and Exchange Commission on June 15, 2021. This draft registration statement has not been publicly filed with the Securities and Exchange Commission and all information herein remains strictly confidential. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington |
|
| June 16, 2021 |
EX-10.11 4 filename4.htm Exhibit 10.11 INDUSTRIAL LEASE – MULTI-TENANT by and between TERRENO PARK UNION CITY LLC “LANDLORD” and TENAYA THERAPEUTICS, INC. “TENANT” Dated: February 12, 2021 TERRENO REALTY CORPORATION INDUSTRIAL LEASE 1. Basic Provisions (“Basic Provisions”). 1.1 Parties: This Lease (“Lease”) dated February 12, 2021, is made by and between Terreno Park Union City LLC, a Delaware lim |
|
| June 15, 2021 |
650 Page Mill Road Palo Alto, CA 94304-1050 650.493.9300 650.493.6811 www.wsgr.com June 15, 2021 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attention: Brian Cascio Tracey Houser Tom Kluck Suzanne Hayes Re: Tenaya Therapeutics, Inc. Draft Registration Statement on Form S-1 Submitted May 7, 2021 |
|
| May 7, 2021 |
Table of Contents As confidentially submitted to the Securities and Exchange Commission on May 7, 2021 This draft registration statement has not been publicly filed with the Securities and Exchange Commission and all information herein remains strictly confidential. |
|
| May 7, 2021 |
BYLAWS OF TENAYA THERAPEUTICS, INC. Adopted August 18, 2016 EX-3.3 3 filename3.htm Exhibit 3.3 BYLAWS OF TENAYA THERAPEUTICS, INC. Adopted August 18, 2016 TABLE OF CONTENTS Page ARTICLE I — MEETINGS OF STOCKHOLDERS 1 1.1 Place of Meetings 1 1.2 Annual Meeting 1 1.3 Special Meeting 1 1.4 Notice of Stockholders’ Meetings 1 1.5 Quorum 2 1.6 Adjourned Meeting; Notice 2 1.7 Conduct of Business 2 1.8 Voting 2 1.9 Stockholder Action by Written Consent Without a M |
|
| May 7, 2021 |
TENAYA THERAPEUTICS, INC. AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT December 17, 2020 EX-4.1 4 filename4.htm Exhibit 4.1 TENAYA THERAPEUTICS, INC. AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT December 17, 2020 TENAYA THERAPEUTICS, INC. AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT This Amended and Restated Investors’ Rights Agreement (this “Agreement”) is dated as of December 17, 2020, and is between Tenaya Therapeutics, Inc., a Delaware corporation (the “Company”), and the |
|
| May 7, 2021 |
EX-10.9 5 filename5.htm Exhibit 10.9 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. [***] INDICATES THAT INFORMATION HAS BEEN REDACTED. LICENSE AGREEMENT This License Agreement (this “Agreement”) is dated as of January 10, 2020 (the “Effective Date”) by and between The Bo |
|
| May 7, 2021 |
AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF TENAYA THERAPEUTICS, INC. EX-3.1 2 filename2.htm Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF TENAYA THERAPEUTICS, INC. Tenaya Therapeutics, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), certifies that: 1. The name of the Corporation is Tenaya Therapeutics, Inc. The Corporation’s original Certificate of Incorporation was filed with the Secretary |
